Recent Updates
Recently added Catalysts

Pyrimethamine

Phase 1

Toxoplasmosis, Cerebral | Small molecule | Infectious Disease |Pfizer, Inc.|Last Updated: Aug 26, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment45
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00000966A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDSPHASE1 COMPLETED 45 - -Aug 26, 200811 United States
Unlock Drug Trial Details
Study Design & Arms
PurposeTREATMENT
Interventions
NameTypeDescription
AzithromycinDRUG -
PyrimethamineDRUG -
Leucovorin calciumDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range13 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria Concurrent Medication: Allowed: * Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia (PCP). * Allowed during maintenance period (weeks 7 - 24): * Zidovudine and other antiretrovirals available through treatment IND mechanisms, ganciclovir, and mainte...

Countries:United States
Unlock Eligibility Criteria